The Granted Patent Covers the Compositions of BTS And BTS(OMe) And Novel Methods Of Their Production

授予的专利涵盖了BTS和BTS（OMe）的组成及其新的生产方法

IRVINE, Calif., March 12, 2024 /PRNewswire/ -- TAE Life Sciences, a leading innovator in cancer treatment technologies, today announced that the United States Patent and Trademark Office (USPTO) has granted the company's U.S. Patent No. US 11,884,688 B2, for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe) for use in Boron Neutron Capture Therapy (BNCT).

加利福尼亚州欧文，2024年3月12日/PRNewswire/--癌症治疗技术的领先创新者TAE Life Sciences今天宣布，美国专利商标局（USPTO）已授予该公司美国专利号US 11884688 B2，因为它具有开创性的硼化氨基酸组成，包括酪氨酸衍生物BTS和BTS（OMe）用于硼中子俘获疗法（BNCT）。

This new patent underscores TAE Life Sciences' commitment to advancing biologically targeted radiation therapy and marks a significant milestone in the field of radiation therapy..

这项新专利强调了TAE Life Sciences对推进生物靶向放射治疗的承诺，标志着放射治疗领域的一个重要里程碑。。

Boron Neutron Capture Therapy (BNCT) is a promising approach for the treatment of cancer and other diseases, utilizing boron-containing compounds to selectively deliver radiation to tumor cells while sparing healthy tissue. TAE Life Sciences' patented borylated amino acid compounds, BTS and BTS(OMe), may offer an effective means of enhancing efficacy of BNCT, potentially opening new avenues for targeted treatments for cancer and immunological disorders..

硼中子俘获疗法（BNCT）是治疗癌症和其他疾病的一种有前途的方法，它利用含硼化合物选择性地向肿瘤细胞传递辐射，同时保留健康组织。TAE Life Sciences获得专利的硼化氨基酸化合物BTS和BTS（OMe）可能为提高BNCT的疗效提供有效手段，可能为癌症和免疫疾病的靶向治疗开辟新途径。。

'This patent represents a significant milestone for TAE Life Sciences, validating the innovative work of our research and development teams. We are excited about the potential impact of BTS and BTS(OMe) in advancing BNCT cancer treatment and improving patient outcomes.' Rob Hill, CEO at TAE Life Sciences..

“这项专利代表了TAE生命科学的一个重要里程碑，验证了我们研发团队的创新工作。我们对BTS和BTS（OMe）在推进BNCT癌症治疗和改善患者预后方面的潜在影响感到兴奋。”TAE生命科学公司首席执行官罗伯·希尔。。

The patent covers not only the compositions of BTS and BTS(OMe) but also novel methods of their production, enabling scalable manufacturing processes to meet the growing demand for BNCT agents. With this patent, TAE Life Sciences solidifies its position as a leader in radiation therapy innovation, poised to transform the landscape of cancer treatment..

该专利不仅涵盖了BTS和BTS（OMe）的组成，还涵盖了其生产的新方法，使可扩展的制造工艺能够满足对BNCT试剂不断增长的需求。凭借这项专利，TAE生命科学巩固了其作为放射治疗创新领导者的地位，有望改变癌症治疗的格局。。

For more information about TAE Life Sciences, Alphabeam, and the company's proprietary boronated BNCT drugs, please visit www.taelifesciences.com.

有关TAE生命科学，Alphabeam和该公司专有硼化BNCT药物的更多信息，请访问www.taelifesciences.com。

About TAE Life SciencesTAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers.

关于TAE Life SciencesTAE Life Sciences是一家私营生物技术公司，致力于开发基于硼中子俘获疗法（BNCT）的新型生物靶向放射疗法。TAE Life Sciences是唯一一家开发下一代靶向硼药物和基于低能加速器的中子系统的公司，该系统针对院内BNCT计划进行了优化，该计划以细胞水平的精确度提供抗癌辐射，以治疗侵袭性和难治性癌症患者。

TAE Life Sciences' Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at www.taelifesciences.com..

TAE生命科学公司的Alphabeam中子系统和靶向硼药物目前正在开发中，尚未批准销售。有关TAE生命科学的更多信息，请访问www.taelifesciences.com。。

Press Contact: Michael Farino New Era Communications 949-346-1984 TAE@newerapr.com

新闻联系人：Michael Farino New Era Communications 949-346-1984TAE@newerapr.com

SOURCE TAE Life Sciences

来源TAE生命科学